A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Public ClinicalTrials.gov record NCT03456063. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Study identification
- NCT ID
- NCT03456063
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 453 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Drug
- Placebo Comparator Drug
- Nab-paclitaxel Drug
- Pemetrexed Drug
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 24, 2018 (Actual)
- Primary completion
- Oct 1, 2025 (Actual)
- Completion
- Dec 31, 2025 (Actual)
- Last update posted
- Oct 9, 2026
2018 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tucson | Arizona | 85711 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange | Orange | California | 92868 | — |
| UC Davis Cancer Center | Sacramento | California | 95817 | — |
| Scripps Clinic | San Diego | California | 92037 | — |
| National Jewish Health | Denver | Colorado | 80206 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Washington Cancer Institute | Washington D.C. | District of Columbia | 20010 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Minnesota Oncology Minneapolis | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Mercy Clinic Cancer & Hematology | Springfield | Missouri | 65804 | — |
| Nebraska Methodist Estabrook Cancer Center | Omaha | Nebraska | 68114 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Lehigh Valley Health Network | Allentown | Pennsylvania | 18103 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology - South Austin | Austin | Texas | 78745 | — |
| Northwest Cancer Specialists - Vancouver | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 93 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03456063, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03456063 live on ClinicalTrials.gov.